Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.55 -0.03%
Revenue Growth %: +23.1%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +23.1%
Financial Fact:
Research and development: 33.86M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $1.60, $0.06 better than the analyst estimate of $1.54. Revenue for the quarter came in at $377 million versus the consensus estimate of $358.45 million.
GUIDANCE:
Halozyme Therapeutics sees FY2026 EPS of $7.75-$8.25, versus the consensus of $8.09. Halozyme Therapeutics sees FY2026 revenue of $1.71-1.81 billion, versus the consensus of $1.76 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Grizzly Discoveries closes private placement raising $349,044
- RBC Capital Downgrades Admiral Group Plc. (ADM:LN) (AMIGY) to Sector Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
